Financial Post EN

NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine for the pharmaceutical industry, today […]

Mar 11, 2026 &03031111202631; 11:03 UTC financialpost.com Trending 4/5

Read original on financialpost.com ↗

↗

Positive for markets

Sentiment score: +75/100

Moderate impact Short-term (days)

WHAT THIS MEANS

NetraMark Holdings Inc. secured a contract with a global biopharmaceutical company to analyze Phase 2 depression trial data using AI-driven solutions, expanding its portfolio in depression and CNS disorder treatments. This agreement demonstrates growing market validation for NetraMark's clinical trial optimization platform and strengthens its position in the precision medicine sector.

AI CONFIDENCE

78% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

AIAI

AIAIStock

Expected to rise

Contract win validates AI platform for pharmaceutical trials; expands revenue pipeline in high-margin clinical trial optimization services

↑

AINMF

AINMFStock

Expected to rise

OTC listing benefits from same positive catalyst as TSX listing; increased visibility in US markets

↑

PF0

PF0Stock

Expected to rise

Frankfurt listing exposure to European investor base; contract demonstrates international market traction

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider accumulating AIAI/AINMF on strength as contract wins validate the AI-driven clinical trial platform. Monitor for additional partnership announcements and Phase 2 trial data milestones that could drive further upside in the near term.

KEY SIGNALS

Contract expansion in depression/CNS disorder marketAI platform validation by major biopharmaceutical partnerRevenue diversification across multiple trial phasesGrowing adoption of precision medicine solutionsMulti-listing liquidity improvement

SECTORS INVOLVED

BiotechnologyPharmaceuticalsArtificial IntelligenceHealthcare TechnologyClinical Research

Analysis generated on Mar 11, 2026 at 11:31 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Financial Post. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

RELATED INTELLIGENCE